Company intelligence / Profile preview
iMetabolic Biopharma Corporation
Tempe, Arizona, United Statesimbiopharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
iMetabolic Biopharma is an early-stage drug discovery company with multiple candidates in discovery and preclinical stages. Their lead asset iMBP-001 is in preclinical development.
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersNephrologyNeurology
- Modalities
- BiologicsAntibodiesFusion proteinsPeptide modulated fusion proteins
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Ligand PharmaceuticalsOmniAbAmazon Web ServicesMcDermott Will & Emery
Beyond the preview
Go deeper on iMetabolic Biopharma Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iMetabolic Biopharma Corporation.